Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse
Telix Pharmaceuticals has signed a strategic agreement to lead a merger with ITM Isotope Technologies Munich SE, paying US$1.65 billion upfront on a cash-free/debt-free basis plus up to US$700 million in contingent milestones tied to ITM-11 FDA approvals and sales. Consideration includes US$1.25 billion in 105.8 million Telix shares priced at US$11.84 (30-day trailing VWAP), assumption of US$302 million of net debt, and US$96 million of equity rollover and transaction expenses; ITM shareholders will own approximately 23.7% of Telix post-close.
Key figures
- Drug Name
- ITM-11 (177Lu-edotreotide)
- Deal Value Usd
- 1650000000
- Phase Of Trial
- Phase 3
- Egm
- November 2026
- Expected close
- end of FY 2026
- Itm revenue 2025
- 273000000
- Net debt assumed
- 302000000
- Itm 11 milestones
- ["US$100 million upon FDA approval for G1-G2 GEP-NETs no later than December 31, 2027","US$100 million upon FDA approval for G2-G3 GEP-NETs no later than December 31, 2030","US$50 million upon FDA approval for Lung NETs no later than December 31, 2031","Up to US$450 million based on ITM-11 net global sales in FY 2030 in excess of US$150 million"]
- Seller escrow period
- up to 15 months
- Proforma 2026 revenue
- exceeding US$1.3 billion
- Share issuance price usd
- 11.84
- Itm revenue cagr 2021 2025
- 40%
- Contingent consideration max
- 700000000
- Equity rollover and expenses
- 96000000
- Proforma ownership itm holders
- 23.7%
- Shares issued as consideration
- 105800000
- Proforma ownership telix holders
- 76.3%
- Nuclear medicine market 2034 forecast
- US$41 billion
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.